Regenxbio (RGNX) Misses Q4 EPS by 58c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.30), $0.58 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $30.34 million versus the consensus estimate of $59.28 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• China retail sales growth slows to 0.6% in July, Macquarie comments
• Active options: NVDA TSLA MU SPCX AAPL AMZN MSFT META INTC